Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia

NCT05215015 | Unknown Early Phase 1

• 2 other identifiers: IBR733-T01WX-IBR-7
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, nonrandomized, investigator-initiated clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of anti-CD33/CLL1 CAR-NK cell injection in patients with acute myeloid leukemia (AML), and to determine PK parameters, maximum tolerated dose (MTD), and phase II recommended dose (RP2D) for subjects receiving CAR-NK cell injection.

Conditions

Acute Myeloid Leukemia

Outcome Measures

Primary Outcomes (1)

• Incidence of dose limiting toxicity (DLT)

  To evaluate the safety and tolerability of Anti-CD33/CLL1 CAR-NK cells

  28 days after initial infusion

Secondary Outcomes (8)

• Overall survival (OS)

  Up to 1 year after infusion

• Minimal residual disease (MRD)

  Up to 1 year after infusion

• Objective response rate (ORR)

  Up to 1 year after infusion

• Duration of overall response (DOR)

  Up to 1 year after infusion

• Plasma concentration of CAR-NK cells

  One month after the last infusion

Study Arms (1)

Anti-CD33/CLL1 CAR-NK Cells

EXPERIMENTAL

The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.

Biological: Anti-CD33/CLL1 CAR-NK Cells

Interventions

Anti-CD33/CLL1 CAR-NK Cells BIOLOGICAL

The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.

Anti-CD33/CLL1 CAR-NK Cells

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects should voluntarily participate in this clinical study, are fully aware of the study, have signed the Informed Consent Forms, and are willing to follow and able to complete all trial procedures.
• Subjects who are more than 18 years old (including 18 years old), and less than 75 years old (including 75 years old);
• Subjects who are diagnosed as AML according to the World Health Organization (WHO) 2016 diagnosis criteria, and meet any of the following:
• Relapsed acute myeloid leukemia: after complete response (CR), there are leukemia cells in peripheral blood or blast cells in bone marrow \>5% (except for other reasons such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration.
• Refractory acute myeloid leukemia: treatment-naive subjects who have no response to the standard of care for 2 courses of treatment; subjects who are relapsed within 12 months with consolidated intensive treatment after CR; subjects who are relapsed after 12 months but have no response to the conventional chemotherapy; subjects who are relapsed twice or more; subjects who have persistent extramedullary leukemia.
• Subjects who are positive in CD33 or CLL1 test (according to the results of the central laboratory);
• Subjects are allowed to have received ≤1 autologous HSCT;
• Subjects whose performance status scores of the Eastern Cooperative Oncology Organization (ECOG) are≤2;
• Subjects with the expected survival phase\>3 months;
• Organ function should meet the following criteria:
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN), unless these are caused by leukemia cell infiltration as determined by the investigator;
• Total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN);
• Glomerular filtration rate (GFR)\>50 mL/min;
• Left ventricular ejection fraction (LVEF)≥50%, no clinically significant pericardial effusion confirmed by echocardiography;
• Blood oxygen saturation under indoor ventilation in the screening phase\>92%;

You may not qualify if:

• Subjects who are known to have acute promyelocytic leukemia;
• Subjects who suffer from or are suspected of suffering from central nervous system leukemia, or central nervous system involvement;
• Subjects who have received allogeneic HSCT;
• Subjects who have prior II-IV (Glucksberg criteria) acute graft versus-host disease (GvHD) or extensive chronic GvHD;
• Subjects who have received chimeric antigen receptor cell therapy or other cell therapy;
• Subjects who have received anti-tumor therapy in the early stage but are not recovered in the toxicity (according to NCI-CTCAE 5.0, the toxicity has not recovered to ≤ Grade 1, except for fatigue, anorexia, and alopecia);
• Subjects whose cardiac function and disease meet one of the following conditions within 6 months before the first administration:
• Any risk factors that increase QTcF (Fridericia formula) interval prolongation, such as uncorrectable hypokalemia, hereditary long QT syndrome, and use of drugs that prolong the QTcF interval;
• New York Heart Association (NYHA) classification ≥Grade 3;
• QTcF interval prolongation (male\>450 milliseconds; female\>470 milliseconds);
• Unstable angina pectoris, and myocardial infarction;
• Subjects who have a history of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.) that require systemic immunosuppressive/systemic disease modulating drugs within 2 years before the first administration;
• Subjects who have active systemic fungal, bacterial or viral infections that are uncontrolled or are required to be treated by intravenous administration;
• Subjects with human immunodeficiency virus (HIV) antibody positive;
• Subjects with HBsAg (-) and HBcAb (-). If subjects have HBsAg (+) and/or HBcAb (+), then subjects with HBV-DNA below the local lower limit of quantification can be included;

Sponsors & Collaborators

• Wuxi People's Hospital: lead
• Imbioray (Hangzhou) Biomedicine Co., Ltd.: collaborator

Study Sites (1)

Wuxi People's Hospital

Wuxi, Jiangsu, China

RECRUITING

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Xin Zhou, MD

CONTACT

+8613358111962; 13625653@qq.com

Peihua Lu, MD

CONTACT

+8613583991399; lyzlyylxm@163.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 18, 2022
• First Posted: January 31, 2022
• Study Start: November 30, 2020
• Primary Completion: November 30, 2022
• Study Completion: November 30, 2022
• Last Updated: January 31, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)